Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 955
Filtrar
2.
Mayo Clin Proc ; 95(8): 1594-1603, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32753134

RESUMO

OBJECTIVE: To examine differences in the frequency and severity of federally reported adverse events between caffeine-containing and non-caffeine-containing products while also identifying the category of caffeine-containing products associated with the highest frequency and severity of adverse events. PATIENTS AND METHODS: All adverse event reports that met specified eligibility criteria and were submitted to the Center for Food Safety and Applied Nutrition Adverse Event Reporting System between January 1, 2014, and June 29, 2018, were extracted. In this retrospective observational study, the most severe adverse event experienced, an ordinal variable, was categorized into death, life-threatening, hospitalization/disability, and emergency department visit. A nonproportional odds model was used to compare the odds of caffeine-containing products being associated with more severe adverse events relative to a noncaffeine group. The analysis is of data only from those reporting adverse events and may or may not be representative of the entire population exposed to these products, which is not known from the examined data. RESULTS: Energy and preworkout products saw a significant increase in the odds of the adverse event experienced being death rather than the other less severe outcomes relative to the noncaffeinated group. Those products, along with weight loss products, had greater odds of the adverse event being death or life-threatening vs the less severe outcomes relative to the noncaffeinated group. CONCLUSION: Caffeine-containing products have a greater association with severe adverse events compared with non-caffeine-containing products. Exposure to preworkout and weight loss products had greater odds of being associated with a more serious adverse event relative to noncaffeinated products. Health care practitioners should use these outcomes to better inform and educate patients about the many factors related to caffeine intake and adverse outcomes.


Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Cafeína/efeitos adversos , United States Food and Drug Administration , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/toxicidade , Cafeína/toxicidade , Bebidas Gaseificadas/efeitos adversos , Bebidas Gaseificadas/toxicidade , Criança , Pré-Escolar , Café/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Suplementos Nutricionais/toxicidade , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Chá/efeitos adversos , Estados Unidos , Adulto Jovem
3.
BMC Health Serv Res ; 20(1): 386, 2020 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-32381084

RESUMO

BACKGROUND: Ideally situated within the community, pharmacists can be involved in a broad range of health promotion campaigns including prevention of obesity. Limited evidence is available regarding their involvement in weight management in Lebanon, a country with escalating prevalence rate of obesity. OBJECTIVE: To examine the role of community pharmacists in weight management in Lebanon, specifically studying their beliefs, current practices, services, and knowledge. METHODS: Using a stratified random sampling approach, a cross sectional national survey of community pharmacists was conducted (n = 341, response rate 89%). At the pharmacy, and through a face-to-face interview, pharmacists completed a multi-component questionnaire that addressed, in addition to socio-demographic and work characteristics, their beliefs, practices, knowledge in relation to weight management. Frequencies and proportions were used to describe the data. Simple and multiple linear regression analyses were used to examine the determinants of knowledge in the study population. RESULTS: Over 80% of study participants agreed that they have an important role to play in weight management. However, 50% of pharmacists did not agree that weight loss products are well regulated and 81.1% thought that companies marketing weight loss products are making false promises. The majority of pharmacists always/often sold weight loss products (84.7%) and counseled their patients for diet (86.3%) and physical activity (91.7%). Despite taking weight and height measurements, 50% of pharmacists rarely/never calculated BMI. Among the pharmacists who reported side effects of weight loss products (46.5%), the majority (91.3%) did so to the pharmaceutical company. The knowledge of pharmacists was better for the use of weight loss products as opposed to their side effects and interactions. Significant predictors of knowledge were holding a Masters/ PhD degree in Pharmacy, graduating from a university inside Lebanon, obtaining weight management training within the academic degree, and receiving inquiries about weight management in the pharmacy more than once daily. CONCLUSIONS: The results of the study provided important insights on the beliefs, practices and knowledge of community pharmacists in weight management in Lebanon. These findings could be used to inform the development of future evidence-based community pharmacists led weight management service provision nationally and internationally.


Assuntos
Obesidade/prevenção & controle , Farmacêuticos/psicologia , Papel Profissional/psicologia , Adulto , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/economia , Estudos Transversais , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Líbano , Masculino , Farmacêuticos/estatística & dados numéricos , Inquéritos e Questionários , Perda de Peso/efeitos dos fármacos
4.
Obesity (Silver Spring) ; 28(7): 1171-1172, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32374528

RESUMO

Obesity treatment is highly stigmatized, mainly because of the stigma of obesity itself. The frequent withdrawal of medications, lorcaserin being the last example, contributes to this stigma, but it is also probably a reflection of it, as data suggest that the threshold for a withdrawal is lower than with other classes of drugs. Safety should always be an absolute priority for every new medication, especially when used on a chronic basis; however, the safety scrutiny given to antiobesity medications is not given for other medications, such as postmenopausal hormone therapy and central nervous system drugs for psychiatric use. The withdrawal of medications for obesity can also impact future research in the area, so we need transparency and equality. Transparency in knowing exactly what reason led to a drug being discontinued and equality in long-term safety should be a concern with any medication prescribed for chronic diseases.


Assuntos
Fármacos Antiobesidade/efeitos adversos , Benzazepinas/efeitos adversos , Doença Crônica/tratamento farmacológico , Medicamentos sob Prescrição/uso terapêutico , Estigma Social , Fármacos Antiobesidade/uso terapêutico , Benzazepinas/uso terapêutico , Doença Crônica/epidemiologia , Humanos , Assistência de Longa Duração , Obesidade/tratamento farmacológico , Obesidade/epidemiologia , Obesidade/psicologia , Medicamentos sob Prescrição/classificação , Vigilância de Produtos Comercializados/normas , Retirada de Medicamento Baseada em Segurança , Estereotipagem , Estados Unidos/epidemiologia , United States Food and Drug Administration/normas
5.
Expert Opin Pharmacother ; 21(11): 1319-1328, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32292094

RESUMO

INTRODUCTION: Pharmacotherapy is a useful adjunct when patients with obesity are unable to achieve adequate benefit from lifestyle interventions. AREAS COVERED: This review covers the history of antiobesity drugs, efficacy, and risks of currently approved drugs, limits of their usefulness in clinical practice, gaps in knowledge, methodological limitations of clinical trials, and reasons for underutilization. EXPERT OPINION: In randomized controlled trials, currently approved antiobesity drugs have yielded an average weight loss ranging from approximately 3% to 9% relative to placebo at 1 year. Inadequate inclusion of racial and ethnic minorities and men, and high dropout rates in clinical trials limit generalizability of these findings to clinical practice. Weight loss achieved with antiobesity drugs is generally associated with lowered glycemia, but improvements in blood pressure and lipid measures tend to be marginal. There is limited evidence for sustained weight loss beyond 1 year and for safety and efficacy of antiobesity drugs in children and adolescents, and in post-bariatric surgery patients. None have demonstrated reduction in major adverse cardiovascular events or other significant disease outcomes. Limited health insurance coverage and negative perceptions of physicians have hindered the utilization of antiobesity drugs.


Assuntos
Fármacos Antiobesidade , Obesidade/tratamento farmacológico , Perda de Peso/efeitos dos fármacos , Adolescente , Fármacos Antiobesidade/administração & dosagem , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/uso terapêutico , Cirurgia Bariátrica , Pressão Sanguínea/efeitos dos fármacos , Criança , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Uso de Medicamentos , Humanos , Estilo de Vida , Resultado do Tratamento
6.
Aliment Pharmacol Ther ; 51(11): 1067-1075, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32319111

RESUMO

BACKGROUND: An association between bariatric surgery and development of de-novo inflammatory bowel disease (IBD) has been observed. AIM: To evaluate further the association among bariatric surgery, weight loss medications, obesity and new-onset IBD. METHODS: Using Explorys, a population-based Health Insurance Portability and Accountability Act compliant database, we estimated the prevalence of de-novo IBD among patients treated with bariatric surgery (Roux-en-Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding) (n = 60 870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide) (n = 193 790) compared with obese controls (n = 5 021 210), between 1999 and 2018. RESULTS: The prevalence of de-novo IBD was lower among obese patients exposed to bariatric surgery (7.72 per 1000 patients) or weight loss medications (7.22 per 1000 patients) compared with patients with persistent obesity not exposed to these interventions (11.66 per 1000 patients, P < 0.0001). The risk reduction for de-novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de-novo IBD compared with the persistent obese control cohort. CONCLUSION: Obese patients undergoing treatment with bariatric surgery or weight loss medications are at a lower risk for developing de-novo IBD compared with persistently obese controls not exposed to these interventions. These data suggest that obesity and ineffective management of obesity are risk factors for de-novo IBD. Further research is needed to confirm these observations and understand potential mechanisms.


Assuntos
Fármacos Antiobesidade/efeitos adversos , Cirurgia Bariátrica/efeitos adversos , Doenças Inflamatórias Intestinais/epidemiologia , Doenças Inflamatórias Intestinais/etiologia , Obesidade Mórbida/cirurgia , Perda de Peso/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Cirurgia Bariátrica/estatística & dados numéricos , Estudos de Coortes , Feminino , Humanos , Doenças Inflamatórias Intestinais/diagnóstico , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/epidemiologia , Prevalência , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Perda de Peso/efeitos dos fármacos , Adulto Jovem
8.
BMJ Case Rep ; 13(3)2020 Mar 31.
Artigo em Inglês | MEDLINE | ID: mdl-32234856

RESUMO

We report two cases of cerebral venous thrombosis associated with the use of compounded preparations containing several active substances prescribed for weight loss. In both cases there is suspicion of additive/synergic interaction with oral contraceptives. The adverse drug reactions were considered serious, being life-threatening and causing hospitalisation for days.


Assuntos
Fármacos Antiobesidade/efeitos adversos , Composição de Medicamentos , Obesidade/tratamento farmacológico , Tromboembolia Venosa/induzido quimicamente , Sistemas de Notificação de Reações Adversas a Medicamentos , Anticoncepcionais Orais/efeitos adversos , Combinação de Medicamentos , Feminino , Humanos , Pessoa de Meia-Idade
9.
J Med Food ; 23(3): 335-342, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32130058

RESUMO

This study investigated the effect of Sinetrol-XPur on weight and body fat reduction in overweight or obese Korean participants. Among 100 overweight or obese participants enrolled in a 12-week randomized, double-blinded, controlled study, 86 participants completed the trial. Participants took either two Sinetrol-XPur tablets (450 mg per tablet) or two placebo tablets once a day. Bodyweight, body fat percentage, body mass index (BMI), body fat mass, waist circumference, and various safety parameters were measured. After the 12-week intervention, a significant reduction was observed in the body fat mass (P = .030) by dual-energy X-ray absorptiometry (DEXA), body weight (P = .002), and BMI (P = .002) compared to the placebo. Body fat percentage (P = .007) by DEXA showed a significant reduction in the Sinetrol-XPur group, but no difference compared to the control group. Abdominal metabolic risks by computed tomography and blood biochemistry analysis were significantly decreased in the Sinetrol-XPur group, but there were no differences between the Sinetrol-XPur and placebo groups. Safety profiles were not different between the two groups. These results suggested that Sinetrol-XPur significantly reduced body weight, body fat mass, and BMI in obese Korean subjects, which confirms the antiobesity effect of Sinetrol-XPur in the Korean population.


Assuntos
Fármacos Antiobesidade/administração & dosagem , Obesidade/tratamento farmacológico , Sobrepeso/tratamento farmacológico , Polifenóis/administração & dosagem , Adulto , Fármacos Antiobesidade/efeitos adversos , Índice de Massa Corporal , Peso Corporal/efeitos dos fármacos , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/fisiopatologia , Sobrepeso/fisiopatologia , Polifenóis/efeitos adversos , Adulto Jovem
10.
Tech Vasc Interv Radiol ; 23(1): 100653, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32192633

RESUMO

Obesity is a public health epidemic in the United States, with implications for patients across many organ systems. Despite improvements in understanding the pathophysiology and increasing number of therapies for obesity, its prevalence continues to rise. The purpose of this review is to provide the interventional radiologist with an understanding of (1) the epidemiology of obesity; (2) the impact of obesity on patients and the healthcare system; (3) the causes of obesity; (4) conservative management of obesity; and (5) pharmacologic management of obesity.


Assuntos
Fármacos Antiobesidade/uso terapêutico , Estilo de Vida Saudável , Obesidade/terapia , Comportamento de Redução do Risco , Fármacos Antiobesidade/efeitos adversos , Regulação do Apetite/efeitos dos fármacos , Dieta Saudável , Exercício Físico , Comportamento Alimentar , Humanos , Obesidade/epidemiologia , Obesidade/fisiopatologia , Obesidade/psicologia , Fatores de Risco , Resultado do Tratamento , Perda de Peso
12.
Open Heart ; 7(1): e001003, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32201580

RESUMO

Spirulina, a cyanobacteria commonly referred to as a blue-green algae, is one of the oldest lifeforms on Earth. Spirulina grows in both fresh and saltwater sources and is known for its high protein and micronutrient content. This review paper will cover the effects of spirulina on weight loss and blood lipids. The currently literature supports the benefits of spirulina for reducing body fat, waist circumference, body mass index and appetite and shows that spirulina has significant benefits for improving blood lipids.


Assuntos
Fármacos Antiobesidade/uso terapêutico , Suplementos Nutricionais , Dislipidemias/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Lipídeos/sangue , Obesidade/tratamento farmacológico , Spirulina , Perda de Peso/efeitos dos fármacos , Animais , Fármacos Antiobesidade/efeitos adversos , Biomarcadores/sangue , Suplementos Nutricionais/efeitos adversos , Dislipidemias/sangue , Dislipidemias/diagnóstico , Humanos , Hipolipemiantes/efeitos adversos , Obesidade/diagnóstico , Obesidade/fisiopatologia , Resultado do Tratamento
13.
Ann Pharmacother ; 54(7): 691-705, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-31958967

RESUMO

Objective: To synthesize the evidence from systematic reviews of clinical trials investigating the effectiveness of pharmacological therapies approved by the Australian Therapeutic Goods Administration and the US Food and Drug Administration for the management of obesity in adults. Data Sources: A 3-step literature search of the MEDLINE, EMBASE, CINAHL, and PubMed databases was conducted between March and May 2019. The key terms used were obesity, pharmacological therapy, antiobesity agent, antiobesity medication, weight loss, and systematic review. Study Selection and Data Extraction: Systematic reviews that evaluated the effectiveness of pharmacological therapies for the management of obesity in patients with a body mass index of or greater than 25 kg/m2. Data Synthesis: Nine systematic reviews involving three pharmacotherapies, liraglutide, orlistat, and naltrexone-bupropion were identified. The results indicate that the pharmacotherapies reduced weight when compared with placebo. Orlistat was effective in significantly reducing fasting blood glucose, HbA1c, total cholesterol, triglycerides, and systolic and diastolic blood pressure. All reviews discussed the presence or risk of gastrointestinal adverse effects including diarrhea, vomiting, and nausea related to orlistat and liraglutide. Relevance to Patient Care and Clinical Practice: This umbrella review compares the efficacy and safety of antiobesity medications for reducing weight and a discussion on their weight loss and metabolic control to guide clinicians when prescribing medications for obesity. Conclusions: All pharmacological therapies included in this review are superior to placebo in reducing weight. Clinicians should consider patient comorbidities and risk of adverse events when recommending medications for weight loss.


Assuntos
Fármacos Antiobesidade/uso terapêutico , Peso Corporal/efeitos dos fármacos , Bupropiona/uso terapêutico , Liraglutida/uso terapêutico , Naltrexona/uso terapêutico , Obesidade/tratamento farmacológico , Orlistate/uso terapêutico , Adulto , Fármacos Antiobesidade/administração & dosagem , Fármacos Antiobesidade/efeitos adversos , Austrália , Pressão Sanguínea/efeitos dos fármacos , Índice de Massa Corporal , Bupropiona/administração & dosagem , Bupropiona/efeitos adversos , Combinação de Medicamentos , Humanos , Liraglutida/administração & dosagem , Liraglutida/efeitos adversos , Naltrexona/administração & dosagem , Naltrexona/efeitos adversos , Orlistate/administração & dosagem , Orlistate/efeitos adversos
15.
Cardiol Young ; 30(1): 131-133, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31902376

RESUMO

A 16-year-old male was admitted to the paediatric ICU with acute onset of vomiting, somnolence, and chest pain, and electrocardiogram showing 2nd degree heart block after ingesting an Aleurites moluccana (Candlenut) seed as a herbal weight loss supplement. Electrocardiogram showed progressively worsening heart block with down-sloping of the ST segments, resembling digoxin toxicity. After 2 days of ICU observation, his symptoms began to improve and eventually resolved. The side effects of herbal supplements are often unknown but by analysing cases such as these, physicians can develop a better understanding of these substances to help guide management.


Assuntos
Aleurites/efeitos adversos , Fármacos Antiobesidade/efeitos adversos , Bloqueio Atrioventricular/induzido quimicamente , Suplementos Nutricionais/efeitos adversos , Adolescente , Aleurites/química , Dor no Peito/etiologia , Eletrocardiografia , Humanos , Masculino , Sementes/efeitos adversos , Perda de Peso
16.
Expert Rev Clin Pharmacol ; 13(2): 183-190, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31815555

RESUMO

Background: Lorcaserin is a novel, selective 5-hydroxytryptamine 2C serotonin receptor agonist, approved for the treatment of obesity. Several phase 3 randomized controlled trials (RCTs) trials have shown a significant reduction in body weight with lorcaserin.Research design and methods: We systematically searched the database of PubMed, Embase, The Cochrane Library and ClinicalTrials.gov up to 31 July 2019 and retrieved all the studies conducted with lorcaserin for ≥1 year that have explicitly reported the efficacy and safety outcomes versus placebo. Subsequently, we studied the effect of lorcaserin on weight reduction, FDA-defined valvulopathy, depression and suicidal risks in RCTs.Results: The meta-analysis of four RCTs (N = 16,856) demonstrated a significant decrease in body weight (mean ∆ -3.076 Kg; 95% CI, -3.49 to -2.66; P < 0.00001), compared to placebo. No significant difference in FDA-defined valvulopathy (RR 1.20; 95% CI, 0.89 to 1.63; P = 0.24), depression (RR 1.07; 95% CI, 0.80 to 1.43; P = 0.67) or suicidal risk (RR 1.43; 95% CI, 0.96 to 2.15; P = 0.08) has been observed with lorcaserin compared to placebo.Conclusions: Lorcaserin reduces body weight modestly, with no obvious serious adverse side effects. The common adverse events noted with lorcaserin include nausea, dizziness, and transient headache.


Assuntos
Benzazepinas/administração & dosagem , Obesidade/tratamento farmacológico , Agonistas do Receptor 5-HT2 de Serotonina/administração & dosagem , Fármacos Antiobesidade/administração & dosagem , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/farmacologia , Benzazepinas/efeitos adversos , Benzazepinas/farmacologia , Peso Corporal/efeitos dos fármacos , Humanos , Obesidade/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Agonistas do Receptor 5-HT2 de Serotonina/efeitos adversos , Agonistas do Receptor 5-HT2 de Serotonina/farmacologia , Perda de Peso/efeitos dos fármacos
17.
Expert Opin Investig Drugs ; 29(1): 63-71, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31847611

RESUMO

Introduction: Obesity is compounded by a neurobiology that is resistant to weight loss. Therefore, the development of pharmacotherapies to address the pathology underlying the dysregulation of energy homeostasis is critical.Areas covered: This review examines selected clinical trial evidence for the pharmacologic treatment of obesity and provides an expert opinion on anti-obesity drug development. The article includes the outcomes of anti-obesity medications that have been evaluated in clinical trials but have not yet received approval from the U.S. Food and Drug Administration. The mechanisms of action of glucagon-like peptide-1 agonists and co-agonists, diabetes medications being investigated for weight loss, and medications acting on the central nervous system as well as peripherally are reviewed. A search was conducted on PubMed using the terms 'Obesity AND Medications' restricted to clinical trials reported in English. Using similar terms, a search was also conducted on ClinicalTrials.gov.Expert opinion: The goal of anti-obesity therapy is finding compounds that are effective and have minimal side effects. Combining medications targeting more than one of the redundant mechanisms driving obesity increases efficacy. However, targeting peripheral mechanisms to overcome the trickle-down effects of centrally acting drugs may be the key to success in treating obesity.


Assuntos
Fármacos Antiobesidade/administração & dosagem , Desenvolvimento de Medicamentos , Obesidade/tratamento farmacológico , Animais , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/farmacologia , Metabolismo Energético/fisiologia , Humanos , Obesidade/fisiopatologia , Perda de Peso/efeitos dos fármacos
19.
J Forensic Sci ; 65(1): 183-188, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31430392

RESUMO

2,4-dinitrophenol (2,4-DNP) is a compound used in the early 1900s as a weight-loss drug but later prohibited due to its severe adverse effects, including death. It has however been attracting interest, due to its weight-loss properties, and appears to be re-emerging in forensic casework. As 2,4-DNP is available for use in industry and as a pesticide and easily accessible online, the dissemination of this drug can be fast. The compound exerts its effects through inhibition of ATP synthesis, and corresponding thermogenic energy loss which can be fatal. A method for qualitative and quantitative analysis of 2,4-DNP in blood and urine specimens using GC-MS with hydrogen as carrier gas is described. The method was validated and displayed acceptable performance parameters with linearity (R2 higher than 0.998), inter-assay imprecision (lower than 10.6%), intra-assay imprecision (lower than 10.7%), and extraction efficiency (92.1%). Stability of 2,4-DNP in blood and urine was studied, and the drug was stable up to 30 days refrigeration or frozen. Six cases in United States suspected to be related to 2,4-DNP were analyzed. Three cases were found to be positive for 2,4-DNP. Concentrations of 2,4-DNP were in the range of 61.6-220 mg/L in urine and <3-114 mg/L in blood. Based on our findings, we suggest that medical examiners and forensic toxicologists be aware of the reappearance of 2,4-DNP, including this compound as a target in death investigations related to weight-loss drugs.


Assuntos
2,4-Dinitrofenol/sangue , 2,4-Dinitrofenol/urina , Fármacos Antiobesidade/sangue , Fármacos Antiobesidade/urina , Cromatografia Gasosa-Espectrometria de Massas/métodos , 2,4-Dinitrofenol/efeitos adversos , Fármacos Antiobesidade/efeitos adversos , Estabilidade de Medicamentos , Feminino , Toxicologia Forense , Humanos , Masculino , Manejo de Espécimes , Estados Unidos , Adulto Jovem
20.
Crit Rev Food Sci Nutr ; 60(10): 1614-1630, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-30896252

RESUMO

Objective: To evaluate the evidence published from 2006 to 2016 on the effectiveness and safety of commonly used natural supplements for weight loss in individuals with obesity.Methods: Amazon and Google were searched for names of mono-agent natural supplements marketed for weight loss and a list of the 10 supplements was created. Google Scholar, Pubmed, Science Direct, and the Cochrane Library were searched for articles that met inclusion.Results: At least one article was published on the effectiveness or safety of bitter orange, capsinoid, carnitine, chromium picolinate, Coleus forskohlii, conjugated linoleic acid, glucomannan, green tea and psyllium for weight loss in populations with obesity from 2006 to 2016. There was insufficient evidence to suggest that the natural supplements examined contribute to significant weight loss, with the exception of perhaps glucomannan in the form of PGX. In general, the majority of side-effects reported were minor to moderate, and gastrointestinal-related. However, in some cases extreme side-effects such as liver and kidney failure were observed.Conclusion: Contrary to popular belief, results of this review suggest that the use of natural supplements for weight loss are unlikely to contribute to meaningful weight loss and in some cases may contribute to harm.


Assuntos
Obesidade/tratamento farmacológico , Perda de Peso/efeitos dos fármacos , Fármacos Antiobesidade/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA